# EDGAR Filing Document

**Accession Number:** 0001811115
**File Stem:** 0001213900-25-068769
**Filing Date:** 2025-7
**Character Count:** 6953
**Document Hash:** de7bcd69974b8bcee6edd3637784798c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-068769.hdr.sgml**: 20250729

**ACCESSION NUMBER**: 0001213900-25-068769

**CONFORMED SUBMISSION TYPE**: POS AM

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250729

**DATE AS OF CHANGE**: 20250729

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Renalytix plc
- **CENTRAL INDEX KEY:** 0001811115
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** POS AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-271579
- **FILM NUMBER:** 251162647

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FINSGATE
- **STREET 2:** 5-7 CRANWOOD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **BUSINESS PHONE:** 44 29 2071 0570

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FINSGATE
- **STREET 2:** 5-7 CRANWOOD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Renalytix AI plc
- **DATE OF NAME CHANGE:** 20200430

**As filed with the Securities and Exchange Commission on July 29, 2025**

**Registration No. 333-271579**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Post-Effective Amendment No. 2 to:**

**Form F-3 Registration No. 333-271579, as amended by**

**Post-Effective Amendment No. 1 on Form S-3**

***UNDER***

***THE SECURITIES ACT OF 1933***

**Renalytix plc**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **England and Wales** | **Not Applicable** |
| **(State or other jurisdiction of** | **(I.R.S. Employer** |
| **incorporation or organization)** | **Identification Number)** |

---

**2 Leman Street**

**London E1W 9US**

**United Kingdom**

**Tel: +44 20 3139 2910**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Renalytix AI, Inc.**

**1460 Broadway**

**New York, NY 10036**

**Tel: +1 646 397 3970**

**(Name, address and telephone number of agent for service)**

***Copies of all communications, including communications sent to agent for service, should be sent to:***

---

| |
|:---|
| **Mark E. Rosenstein** |
| **Stevens & Lee PC** |
| **620 Freedom Business Center, Suite 200** |
| **King of Prussia, PA 19406** |
| **+1 610 205-6050** |

---

**APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: This post-effective amendment is being filed to deregister the unsold securities previously registered under this Registration Statement.**

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

**DEREGISTRATION OF SECURITIES**

This Post-Effective Amendment No. 2 relates to the following Registration Statement (the "***Registration Statement***"), filed with the Securities Exchange Commission (the "***SEC***") by Renalytix plc (the "***Registrant***"):

● Registration Statement No. 333-271579 on Form F-3, originally filed with the SEC on [May 2, 2023](https://www.sec.gov/Archives/edgar/data/1811115/000119312523132566/d443491df3.htm) , as amended by the Post-Effective Amendment No. 1 on Form S-3 on [September 28, 2023](https://www.sec.gov/Archives/edgar/data/1811115/000119312523244702/d490005dposam.htm) .

The Registrant is filing this Post-Effective Amendment to deregister any and all securities that remain unsold under the Registration Statement as of the date hereof. In accordance with the undertakings made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof.

**SIGNATURE**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of London, United Kingdom, on July 29, 2025.

---

| | | |
|:---|:---|:---|
| **RENALYTIX PLC** | **RENALYTIX PLC** | **RENALYTIX PLC** |
| By: | /s/ James McCullough | /s/ James McCullough |
|  | Name: | James McCullough |
|  | Title: | Chief Executive Officer |

---

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.